JP2020127426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020127426A5 JP2020127426A5 JP2020084311A JP2020084311A JP2020127426A5 JP 2020127426 A5 JP2020127426 A5 JP 2020127426A5 JP 2020084311 A JP2020084311 A JP 2020084311A JP 2020084311 A JP2020084311 A JP 2020084311A JP 2020127426 A5 JP2020127426 A5 JP 2020127426A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- cancer
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- 230000001965 increasing effect Effects 0.000 claims 8
- 108090000695 Cytokines Proteins 0.000 claims 7
- 102000004127 Cytokines Human genes 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 210000003289 regulatory T cell Anatomy 0.000 claims 7
- 210000004881 tumor cell Anatomy 0.000 claims 7
- 230000006052 T cell proliferation Effects 0.000 claims 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 101000738584 Homo sapiens C-C chemokine receptor type 4 Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 4
- 102000043444 human CCR4 Human genes 0.000 claims 4
- 201000005962 mycosis fungoides Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000028327 secretion Effects 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 108700012439 CA9 Proteins 0.000 claims 3
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 3
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229960001212 bacterial vaccine Drugs 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022086515A JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642749P | 2012-05-04 | 2012-05-04 | |
| US61/642,749 | 2012-05-04 | ||
| US201361785559P | 2013-03-14 | 2013-03-14 | |
| US61/785,559 | 2013-03-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018120054A Division JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022086515A Division JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020127426A JP2020127426A (ja) | 2020-08-27 |
| JP2020127426A5 true JP2020127426A5 (enExample) | 2020-10-15 |
Family
ID=48428719
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510508A Active JP6411329B2 (ja) | 2012-05-04 | 2013-05-06 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2018120054A Active JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2020084311A Pending JP2020127426A (ja) | 2012-05-04 | 2020-05-13 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2022086515A Withdrawn JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510508A Active JP6411329B2 (ja) | 2012-05-04 | 2013-05-06 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2018120054A Active JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022086515A Withdrawn JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9441045B2 (enExample) |
| EP (2) | EP3511343A1 (enExample) |
| JP (4) | JP6411329B2 (enExample) |
| AU (1) | AU2013256010B2 (enExample) |
| CA (1) | CA2871751C (enExample) |
| HK (1) | HK1207655A1 (enExample) |
| WO (1) | WO2013166500A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2585004B2 (ja) | 1987-07-15 | 1997-02-26 | 太洋鋳機株式会社 | 連続式混練機における自動清掃装置 |
| HK1207655A1 (en) * | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| EP3054975A4 (en) * | 2013-10-11 | 2017-06-28 | Sloan-Kettering Institute for Cancer Research | Methods and compositions for regulatory t-cell ablation |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016057488A1 (en) * | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| RU2017125531A (ru) | 2014-12-19 | 2019-01-21 | Дана-Фарбер Кэнсер Инститьют, Инк. | Химерные антигенные рецепторы и способы их применения |
| WO2016178779A1 (en) * | 2015-05-01 | 2016-11-10 | Dana-Farber Cancer Institute, Inc. | Methods of mediating cytokine expression with anti ccr4 antibodies |
| IL313952A (en) | 2015-12-22 | 2024-08-01 | Regeneron Pharma | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| CA3037518A1 (en) | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
| EP3526257A2 (en) | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| EP3585812A1 (en) | 2017-02-21 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US11730736B2 (en) | 2017-11-06 | 2023-08-22 | Rapt Therapeutics, Inc. | Anticancer agents |
| CN108250290B (zh) | 2018-02-23 | 2024-03-12 | 上海捌加壹医药科技有限公司 | Ccr4的n端重组蛋白及其用途 |
| JP2021518104A (ja) | 2018-03-14 | 2021-08-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 |
| EP3820517A4 (en) * | 2018-07-11 | 2022-04-06 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO CCR4-TARGETED FC ANTIGEN-BINDING DOMAIN CONSTRUCTIONS |
| AU2020290579A1 (en) | 2019-06-14 | 2021-12-16 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 and methods of use thereof |
| CN113388640B (zh) * | 2020-06-11 | 2022-12-20 | 百奥赛图(北京)医药科技股份有限公司 | Ccr4基因人源化的非人动物及其构建方法和应用 |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2024163530A2 (en) * | 2023-02-01 | 2024-08-08 | Crown Bioscience Inc. | Novel anti-ccr4 antibodies and derivative products |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| KR100252547B1 (ko) | 1991-09-05 | 2000-09-01 | 프레드 마리얀스키 | 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달 |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US8962806B2 (en) * | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| HK1207655A1 (en) * | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2013
- 2013-05-06 HK HK15108293.0A patent/HK1207655A1/xx unknown
- 2013-05-06 JP JP2015510508A patent/JP6411329B2/ja active Active
- 2013-05-06 AU AU2013256010A patent/AU2013256010B2/en active Active
- 2013-05-06 US US14/398,910 patent/US9441045B2/en active Active
- 2013-05-06 CA CA2871751A patent/CA2871751C/en active Active
- 2013-05-06 EP EP18209618.0A patent/EP3511343A1/en active Pending
- 2013-05-06 EP EP13722266.7A patent/EP2844674A1/en not_active Ceased
- 2013-05-06 WO PCT/US2013/039744 patent/WO2013166500A1/en not_active Ceased
-
2015
- 2015-08-07 US US14/820,882 patent/US9587028B2/en active Active
-
2017
- 2017-01-27 US US15/418,510 patent/US20180094064A1/en not_active Abandoned
-
2018
- 2018-06-25 JP JP2018120054A patent/JP6704954B2/ja active Active
- 2018-12-17 US US16/222,342 patent/US20190276544A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084311A patent/JP2020127426A/ja active Pending
-
2022
- 2022-05-27 JP JP2022086515A patent/JP2022119907A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020127426A5 (enExample) | ||
| JP2015517470A5 (enExample) | ||
| JP2022159548A5 (enExample) | ||
| JP2020193210A5 (enExample) | ||
| JP2020103301A5 (enExample) | ||
| CN111944050B (zh) | 一种抗b7-h3抗体及其应用 | |
| JP2013502913A5 (enExample) | ||
| JP2022093564A5 (enExample) | ||
| JP2021508255A5 (enExample) | ||
| JP2013227339A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2017537972A5 (enExample) | ||
| JP2017531427A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2019513777A5 (enExample) | ||
| KR102857892B1 (ko) | 항-인간 vsig4 항체 및 이의 용도 | |
| JP2020522474A5 (enExample) | ||
| CN117321087A (zh) | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 | |
| WO2023000791A1 (en) | Antibodies against ror1 and uses thereof | |
| JP2018518465A5 (enExample) | ||
| CN118871467A (zh) | 抗pd-l2抗体 | |
| JPWO2021155380A5 (enExample) | ||
| TWI828626B (zh) | 併用包含溶血性鏈球菌之菌體的製劑的療法 | |
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 |